Dr. Tanya Dempsey is a board-certified internal medicine physician from Johns Hopkins who specializes in integrated medicine and mast cell activation syndrome (MCAS). She operates the AIM Center for Personalized Medicine in Westchester County, New York, where she has established specialized laboratory facilities for diagnosing and treating complex inflammatory conditions.

The conversation explores mast cell activation syndrome, a chronic inflammatory multi-system condition affecting up to 20% of the population. Dr. Dempsey explains how dysfunctional mast cells constantly release inflammatory chemicals, creating symptoms that mimic allergies, IBS, anxiety, chronic fatigue, POTS, and dozens of other conditions. She discusses her groundbreaking research published in The Consensus II Criteria for Diagnosis and Management of Patients with Mast Cell Syndromes and her recent study on The Utility of GLP-1 Receptor Agonists in Mast Cell Activation Syndrome.

The discussion covers the connection between MCAS and underlying infections like chronic Lyme, Epstein-Barr virus, and parasites, along with innovative treatment approaches including therapeutic plasma exchange, SOT therapy, and the surprising effectiveness of GLP-1 receptor agonists in stabilizing mast cells directly.

Understanding Mast Cell Activation Syndrome

Mast cell activation syndrome is a chronic inflammatory multi-system condition where mast cells constantly leak inflammatory chemicals, causing baseline inflammation throughout the body.

Everyone has mast cells as front-line immune defenders, but in MCAS they become dysfunctional and 'constantly sense something is wrong,' releasing over 1,200 different chemical mediators without actual threats.

The condition presents in three main themes: chronic inflammation, allergic-type phenomena (often with negative allergy tests), and abnormal cell growth including tumors, cysts, and connective tissue disorders.

MCAS affects up to 17-20% of the population and mimics dozens of conditions including allergies, IBS, anxiety, chronic fatigue, fibromyalgia, POTS, and skin issues.

The PCOS-MCAS Connection

"Right now, in my practice, 100% of patients with PCOS have mast cell activation syndrome" - Dr. Dempsey considers them essentially the same condition.

Hormonal changes, particularly estrogen fluctuations, can trigger mast cell activation, explaining why women often see symptom changes around puberty and menstrual cycles.

Mast cells release heparin, which may explain why some women with MCAS experience extremely heavy menstrual periods due to blood thinning effects.

Diagnostic Challenges and Testing

Testing for MCAS requires measuring inflammatory mediators in blood and urine, but samples must be carefully refrigerated and processed by specialized labs equipped for proper handling.

Dr. Dempsey co-authored The Consensus II Criteria for Diagnosis and Management of Patients with Mast Cell Syndromes to establish standardized diagnostic protocols for the medical community.

"It's a clinical diagnosis" - Dempsey explains that if patients have inflammatory multi-system symptoms without other explanations, it's most likely MCAS even if tests are inconclusive.

Many patients receive negative test results in community settings due to improper sample handling, leading to missed diagnoses and continued suffering.

GLP-1 Breakthrough for Mast Cell Treatment

Dr. Dempsey's study The Utility of GLP-1 Receptor Agonists in Mast Cell Activation Syndrome examined 47 patients treated with semaglutide or tirzepatide, showing dramatic improvement across multiple body systems.

Mast cells have GLP-1 and GIP receptors on their surface that act like 'satellites scanning the environment' - these drugs bind directly to mast cells sending 'all is well, calm down' signals.

The treatment works by directly stabilizing mast cells rather than addressing downstream inflammation, allowing the body to heal from chronic inflammatory damage.

Chronic Infections as MCAS Triggers

"I've never seen so many" positive PCR tests for Epstein-Barr virus replication post-COVID, with patients experiencing cycles of dormancy and reactivation for years.

Chronic Lyme, Bartonella, Babesia, and reactivated viruses constantly trigger mast cells, creating 'vicious cycles of immune dysfunction becoming worse and worse.'

"You're never going to kill all the Epstein-Barr. You're never going to kill all the Lyme" - treatment focuses on reducing pathogen load while building immune system capacity to keep infections dormant.

Dr. Dempsey uses SOT (Supportive Oligonucleotide Technique) therapy, creating synthetic RNA to match specific pathogens' DNA, causing them to stop multiplying and die.

Parasite Connection and Immune Suppression

75% of MCAS patients test positive for cryptosporidium, a parasite traditionally only seen in severely immunocompromised HIV or cancer patients.

"That tells me that part of this mast cell activation syndrome is suppressing the immune system so much that we're seeing parasites that should not be in relatively healthy people."

Parasite testing requires multiple attempts as they 'stick to intestinal walls like Spider-Man with suction cups' and may not appear in every stool sample.

Treatment requires pharmaceutical antiparasitics like ivermectin, fenbendazole, and albendazole in sequential protocols - 'you need the drugs, you got to bring the big guns.'

Advanced Detoxification Therapies

Therapeutic plasma exchange removes toxins, biofilms, and inflammatory mediators that conventional treatments cannot eliminate, with visible plasma clearing over multiple sessions.

Dr. Dempsey conducts studies showing TPE removes BPA, PFAS forever chemicals, and microplastics, with before-and-after blood analysis confirming toxin reduction.

Biofilms create 'spider web' structures holding pathogens together - sometimes requiring anticoagulants like heparin to thin blood enough for antimicrobials to reach hidden infections.

Treatment must be personalized as many MCAS patients cannot tolerate standard therapies like saunas due to heat sensitivity, requiring alternative detoxification approaches.